Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1034-1040

  Blanchet, P J ^a,b,d   Konitsiotis, S ^a   Whittemore, E R ^a,c   Zhou, Z L ^a,c   Woodward, R M ^a,c   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Department of Pharmacokinetics and Drug Metabolism   (United States)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 HYDROXY N [2 (4 HYDROXYPHENOXY)ETHYL] 4 (4 METHYLBENZYL)PIPERIDINE; 4 OXO 5 PHOSPHONONORVALINE; LEVODOPA; MDL 100453; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG POTENTIATION; DYSKINESIA; MONKEY; MOTOR PERFORMANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; MPTP POISONING; OOCYTES; PARKINSON DISEASE, SECONDARY; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; VALINE; XENOPUS LAEVIS;

EID: 0032797570     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Blanchet PJ, Konitsiotis S and Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802.
2. Blanchet PJ, Verhagen Metman L, Mouradian MM and Chase TN (1996) Acute pharmacological blockade of dyskinesias in Parkinson's disease. Mov Disord 11: 580-581.
3. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA and Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484.
4. Close SP, Elliott PJ, Hayes AG and Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102:295-300.
5. Crossman AR, Peggs D, Boyce S, Luquin MR and Sambrook MA (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28:1271-1273.
6. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 264:221-225.
7. Engber TM, Papa SM, Boldry RC and Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586-2588.
8. Fischer G, Mutel V, Trube G, Malherbe JN, Kew JNC, Mohacsi E, Heitz MP and Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
9. Gallagher MJ, Huang H, Prichett DB and Lynch DR (1996) Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271:9603-9611.
10. Gomez-Mancilla B, Boucher R, Gagnon C, Di Paolo T, Markstein R and Bédard PJ (1993) Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov Disord 8:144-150.
11. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R and Gash DM (1994) Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 35:655-661
12. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Ann Rev Neurosci 17:31-108.
13. Löschmann P-A, Lange KW, Kunow M, Rettig K-J, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P and Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm [P-D Sect]3:203-213.
14. Luo JH, Wang YH, Yasuda RP, Dunah AW and Wolfe BB (1997) The majority of N-methyl-D-aspartate receptor complexes in adult cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol Pharmacol 51:79-86.
15. Lynch DR and Gallagher MJ (1996) Inhibition of N-methyl-D-aspartate receptors by haloperidol: Developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 279:154-161.
16. Marsden CD (1990) Parkinson's disease. Lancet 335:948-952.
17. Monyer H, Burnashev N, Laurie DJ, Sakmann B and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
18. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B and Seeburg PH (1992) Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256:1217-1221.
19. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N and Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31-37.
20. Nash JE, Fox SH, Henry B, Hill MP, Hille CJ, Maneuf YP, Peggs D, McGuire S, Crossman AR and Brotchie JM (1997) Anti-parkinsonian effect of NR2B-selective NMDA antagonists in animal models of Parkinson's disease: A striatal mechanism of action? Soc Neurosci Abstr 23:187.
21. Oh JD, Del Dotto P and Chase TN (1997) Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 228:5-8.
22. Oh JD, Russell D, Vaughan CL and Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and L-DOPA administration. Brain Res 813:150-159.
23. Papa SM, Boldry RC, Engber TM, Kask AM and Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18.
24. Papa SM and Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39:574-578.
25. Priestly T, Laughton P, Myers J, Le Bourdelles B, Kirby J and Whiting PJ (1995) Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol 48:841-848.
26. Robertson RG, Farmery SM, Sambrook MA and Crossman AR (1989) Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res 476:317-322.
27. Rupniak NMJ, Boyce S, Steventon MJ, Iversen SD and Maraden CD (1992) Dystonia induced by combined treatment with L-DOPA and MK-801 in parkinsonian monkeys. Ann Neurol 32:103-105.
28. Sheng M, Cummings J, Roldan LA, Jan YN and Jan LY (1994) Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature (Lond) 368:144-147.
29. Steece-Collier K, Pazmino R and Greenamyre JT (1995) Antiparkinsonian effects of the novel NMDA antagonist CP-101,606. Soc Neurosci Abstr 21:1256.
30. Stocca G and Vicini S (1998) Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J Physiol (Lond) 507:13-24.
31. Whittemore ER, Ilyin VI, Konkoy CS and Woodward RM (1997) Subtype-selective antagonism of NMDA receptors by nylidrin. Eur J Pharmacol 337:197-208.
32. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-889.
33. Woodward RM, Huettner JE, Guastella J, Keana JFW and Weber E (1995) In vitro pharmacology of ACEA-1021 and ACEA-1031: Systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 47:568-581.
34. Wüllner U, Kupsch A, Arnold G, Renner P, Scheid C, Scheid R, Oertel W and Klockgether T (1992) The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology 31:713-715.
35. Zhou ZL, Cai SX, Yuen PW, Wise LD, Whittemore ER, Konkoy CS, Weber E, Woodward RM and Keana JFW (1998) Synthesis and SAR of 4-benzyl-4-hydroxy-N-(hydroxyphenoxyalkyl)-piperidines as subtype selective NMDA receptor antagonists (Abstract). 210th ACS National Meeting, Boston, MA, August 23-27, 1998 J Med Chem 115.
36. Zukin RS and Bennett MVL (1995) Alternatively spliced isoforms of the NMDAR1 receptor subunit. Trends Neurosci 8:306-313.